Indegene Limited

INDGN

INE065X01017

Business Support Services

Delayed NSE India S.E. Other stock markets 03:46:00 10/07/2025 pm IST			5-day change	1st Jan Change
570.75 ^INR	-0.59%		+0.79%	-5.46%

03/07	Indegene Partners with FAST India to Boost Biotech Innovation and Academia-Industry Collaboration	MT
01/07	Nomura Adjusts Indegene's Price Target to INR650 From INR570, Keeps at Neutral	MT

Nomura Adjusts Indegene's Price Target to INR650 From INR570, Keeps at Neutral

Published on 01/07/2025 at 17:01

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Indegene Limited

Indegene Partners with FAST India to Boost Biotech Innovation and Academia-Industry Collaboration	03/07	MT
Nomura Adjusts Indegene's Price Target to INR650 From INR570, Keeps at Neutral	01/07	MT
An undisclosed buyer agreed to acquire an unknown minority stake in Indegene Limited from CA Dawn Investments.	06/06	CI
The Indian Institute of Cerebral Palsy and Indegene Partner to Enable A More Inclusive Society	19/05	CI
The Indian School of Public Policy and Indegene Announce Strategic Collaboration to Advance Health Policy Research and Design	06/05	CI
Nomura Adjusts Indegene's Price Target to INR570 From INR590, Keeps at Neutral	30/04	MT
Indegene Logs Higher Fiscal Q4 Consolidated Net Profit	29/04	MT
Indegene Limited, Q4 2025 Earnings Call, Apr 29, 2025	29/04
Indegene Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2025	28/04	CI
Nomura Adjusts Indegene's Price Target to INR590 From INR660, Keeps at Neutral	03/04	MT
Indegene Expands Presence in Europe, Announces New Center in London	19/03	CI
Indegene Ireland Limited announced that it expects to receive ?3.098208 million in funding from Indegene Limited	19/03	CI
Indegene Launches Generative AI Platform Cortex for Life Sciences	24/02	MT
Indegene Launches Cortex, A Fit-For-Purpose Generative Ai Platform	24/02	CI
Indegene Limited Launches New Entity in Spain	06/02	CI
Indegene Seeks Acquisitions	31/01	CI
Indegene Limited, Q3 2025 Earnings Call, Jan 31, 2025	31/01
Indegene Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	30/01	CI
Indegene, CliniOps Tie Up to Enhance Clinical Trial Efficiency	10/01	MT
CliniOps, Inc. Announces Strategic Partnership with Indegene to Accelerate Clinical Trials	09/01	CI
Nomura Adjusts Indegene's Price Target to INR660 From INR680, Keeps at Neutral	03/01	MT
Indegene Opens New Centers in Hyderabad, India	18/11	MT
Indegene Expands Global Delivery Network, Announces A New Center in Hyderabad	18/11	CI
192,525,083 Equity Shares of Indegene Limited are subject to a Lock-Up Agreement Ending on 10-NOV-2024.	10/11	CI
Nomura Adjusts Indegene's Price Target to INR680 From INR700, Keeps at Neutral	30/24/30	MT

Indegene Limited is a life sciences commercialization company. It provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies. The Company operates through four segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Its Enterprise Commercial Solutions segment primarily involves assisting life sciences companies with their digital marketing operations. Its Omnichannel Activation solutions segment helps life sciences companies leverage a digital first approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to healthcare professionals across multiple channels. Under its Enterprise Medical Solutions segment, it establishes centers of excellence to consolidate large scale regulatory and medical operations for its clients. Others segment offers enterprise clinical solutions and consultancy services.

Employees

4,158

Sector

Business Support Services

Calendar

31/07 - Q1 2026 Earnings Release (Projected)

More about the company